ASTEC Stock Overview
Astec LifeSciences Limited produziert, vertreibt und verkauft zusammen mit seinen Tochtergesellschaften agrochemische Wirkstoffe und pharmazeutische Zwischenprodukte in Indien.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 2/6 |
Astec LifeSciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,157.80 |
| 52 Week High | ₹1,541.65 |
| 52 Week Low | ₹825.05 |
| Beta | 0.31 |
| 1 Month Change | 17.95% |
| 3 Month Change | 6.19% |
| 1 Year Change | -14.74% |
| 3 Year Change | 8.05% |
| 5 Year Change | 127.29% |
| Change since IPO | 1,278.33% |
Recent News & Updates
Recent updates
Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Mar 15
Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate Capital
May 17Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In Value
Oct 14We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease
Jul 27Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly
Jun 28A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)
Jun 03Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)
May 08Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 06Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)
Jan 25Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?
Dec 13We Take A Look At Why Astec LifeSciences Limited's (NSE:ASTEC) CEO Has Earned Their Pay Packet
Jul 21Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?
May 02The Trend Of High Returns At Astec LifeSciences (NSE:ASTEC) Has Us Very Interested
Apr 17Do Astec LifeSciences's (NSE:ASTEC) Earnings Warrant Your Attention?
Apr 02Is Astec LifeSciences Limited's (NSE:ASTEC) Shareholder Ownership Skewed Towards Insiders?
Mar 18Have Insiders Been Selling Astec LifeSciences Limited (NSE:ASTEC) Shares?
Mar 05Did You Miss Astec LifeSciences' (NSE:ASTEC) Whopping 481% Share Price Gain?
Feb 20A Look At Astec LifeSciences' (NSE:ASTEC) CEO Remuneration
Feb 08Declining Stock and Solid Fundamentals: Is The Market Wrong About Astec LifeSciences Limited (NSE:ASTEC)?
Jan 28What Does Astec LifeSciences Limited's (NSE:ASTEC) Share Price Indicate?
Jan 17
Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)
Jan 08I Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease
Dec 28Is Astec LifeSciences Limited (NSE:ASTEC) Popular Amongst Insiders?
Dec 18Astec LifeSciences (NSE:ASTEC) Is Growing Earnings But Are They A Good Guide?
Dec 07Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?
Nov 27Ashok Hiremath Is The MD & Director of Astec LifeSciences Limited (NSE:ASTEC) And They Just Sold 35% Of Their Shares
Nov 17Shareholder Returns
| ASTEC | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | 8.5% | 4.2% | 3.6% |
| 1Y | -14.7% | 22.3% | 48.8% |
Rendite im Vergleich zur Industrie: ASTEC unter dem Niveau der Branche Indian Chemicals , die im vergangenen Jahr eine Rendite von 20.5% erzielte.
Rendite vs. Markt: ASTEC hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von 45.9 erzielte.
Price Volatility
| ASTEC volatility | |
|---|---|
| ASTEC Average Weekly Movement | 6.6% |
| Chemicals Industry Average Movement | 6.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.4% |
| 10% least volatile stocks in IN Market | 4.2% |
Stabiler Aktienkurs: ASTECDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.
Volatilität im Zeitverlauf: ASTECDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 551 | Anurag Roy | https://www.astecls.com |
Astec LifeSciences Limited produziert, vertreibt und verkauft zusammen mit seinen Tochtergesellschaften agrochemische Wirkstoffe und pharmazeutische Zwischenprodukte in Indien. Zu den Produkten gehören Triazolfungizide, heterozyklische Herbizide, Sulfonylharnstoff-Herbizide, synthetische Pyrethroide, Alkyl- und Arylmagnesiumhalogenide, gemischte Metallhalogenide und Silanderivate; fluorierte aromatische, aliphatische und heterozyklische Zwischenprodukte; fluorierte aromatische Amine, Pyridinderivate, aromatische Carbonsäuren, Benzylalkohole, Ketone und Benzophenone sowie heterozyklische Mercaptane; heterocyclische Mercaptane, Thiopyrimidine und aromatische Mercaptane; heterocyclische Sulfonylchloride, Sulfonamide und Carbamate; Thiouriumsalze, Alkyl- und Arylchlorameisensäureester, substituierte Pyrimidindione und Pyrazolone sowie substituierte 1,2- und 1,3-Pyrimidine. Die Produkte des Unternehmens umfassen außerdem aromatische Pyrazolylketone, Morpholinderivate, aromatische Azoverbindungen, substituierte Triazine, Imidatether, mesylierte Zwischenprodukte, substituierte Epoxide, Ketale und Bromketale, aromatische und aliphatische Ether, Cyclopropylether, Cyclopropylaldehyde und -ketone, konjugierte Ketone, Acetophenonderivate, Pinacolonderivate, aliphatische und aromatische Carbonsäuren, aliphatische und aromatische Säurechloride, halogenierte und nichthalogenierte Anhydride, aliphatische Alkene und Halogenalkane; und aliphatische und aromatische bromierte Derivate, Cyanide, Ester, Carboxamide, Amine, Alkohole und Diole.
Astec LifeSciences Limited Fundamentals Summary
| ASTEC fundamental statistics | |
|---|---|
| Market cap | ₹22.39b |
| Earnings (TTM) | -₹509.39m |
| Revenue (TTM) | ₹4.32b |
5.3x
P/S Ratio-44.6x
P/E RatioIs ASTEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASTEC income statement (TTM) | |
|---|---|
| Revenue | ₹4.32b |
| Cost of Revenue | ₹3.06b |
| Gross Profit | ₹1.26b |
| Other Expenses | ₹1.77b |
| Earnings | -₹509.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -25.98 |
| Gross Margin | 29.16% |
| Net Profit Margin | -11.80% |
| Debt/Equity Ratio | 109.2% |
How did ASTEC perform over the long term?
See historical performance and comparison